WB result of Phospho-c-Myc (Ser62) Recombinant Rabbit mAb
Blocking/Diluting buffer and concentration: 5% NFDM/TBST
Primary antibody: Phospho-c-Myc (Ser62) Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: untreated Karpas-299 whole cell lysate 20 µg
Lane 2: Karpas-299 treated with 10 µM MG-132 overnight whole cell lysate 20 µg
Lane 3: untreated HCT 116 whole cell lysate 20 µg
Lane 4: HCT 116 treated with 10 µM MG-132 overnight whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 62 kDa
Observed MW: 62 kDa
This blot was developed with high sensitivity substrate
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | Phospho-c-Myc (Ser62) |
| Synonyms | Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39 (bHLHe39); Proto-oncogene c-Myc; Transcription factor p64; BHLHE39; MYC |
| Location | Cytoplasm, Nucleus |
| Accession | P01106 |
| Clone Number | S-3428 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | WB |
| Reactivity | Hu, Ms, Rt |
| Positive Sample | Karpas-299, HCT-116 |
| Purification | Protein A |
| Concentration | 0.5 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application | dilution | species |
| WB | 1:1000 | Hu, Ms, Rt |
Background
Phospho-c-Myc (Ser62) is the c-Myc transcription factor phosphorylated at serine-62, an essential post-translational modification that stabilizes the protein by preventing ubiquitin-mediated degradation, thereby sustaining c-Myc’s ability to drive expression of genes governing cell-cycle progression, metabolism and apoptosis; this phosphorylation, primarily catalyzed by ERK or CDK kinases in response to mitogenic signals, is tightly balanced by de-phosphorylation at Thr58 to trigger subsequent degradation, and its dysregulation is frequently observed in cancers where elevated phospho-Ser62-c-Myc levels correlate with hyper-proliferation and poor prognosis, making it both a biomarker and a potential therapeutic target.
Picture
Picture
Western Blot
